Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medicine and Health Sciences (5)
- Life Sciences (4)
- Bioethics and Medical Ethics (3)
- Biostatistics (2)
- Laboratory and Basic Science Research (2)
-
- Public Health (2)
- Bioinformatics (1)
- Biotechnology (1)
- Cardiovascular Diseases (1)
- Chemicals and Drugs (1)
- Clinical Epidemiology (1)
- Diseases (1)
- Genetics (1)
- Genetics and Genomics (1)
- Genomics (1)
- Health Law and Policy (1)
- Health Services Research (1)
- Law (1)
- Longitudinal Data Analysis and Time Series (1)
- Medical Pharmacology (1)
- Medical Sciences (1)
- Medical Specialties (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Neurology (1)
- Pharmaceutical Preparations (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Institution
- Keyword
-
- Clinical trials (3)
- Abigail Alliance (1)
- Adaptation (1)
- Adult (1)
- Alzheimer (1)
-
- Animal models (1)
- Attitudes (1)
- Bayesian statistical decision theory (1)
- Biochemical markers (1)
- Cancer (1)
- Clinical protocols (1)
- Clinical trial (1)
- Comprehension (1)
- Cost of illness (1)
- Dementia (1)
- Diagnosis (1)
- Dirichlet principle (1)
- Drug development (1)
- England (1)
- Epilepsy (1)
- FDA (1)
- Feasibility studies (1)
- Female (1)
- GERA (1)
- GWAS (1)
- Genomics (1)
- Health knowledge (1)
- Health literacy (1)
- Humans (1)
- Hydrochlorothiazide (1)
- Publication
- Publication Type
Articles 1 - 6 of 6
Full-Text Articles in Clinical Trials
Wordless Intervention For Epilepsy In Learning Disabilities (Wield): Study Protocol For A Randomized Controlled Feasibility Trial, Marie-Anne Durand, Bob Gates, Georgina Parkes, Asif Zia
Wordless Intervention For Epilepsy In Learning Disabilities (Wield): Study Protocol For A Randomized Controlled Feasibility Trial, Marie-Anne Durand, Bob Gates, Georgina Parkes, Asif Zia
Dartmouth Scholarship
Epilepsy is the most common neurological problem that affects people with learning disabilities. The high seizure frequency, resistance to treatments, associated skills deficit and co-morbidities make the management of epilepsy particularly challenging for people with learning disabilities. The Books Beyond Words booklet for epilepsy uses images to help people with learning disabilities manage their condition and improve quality of life. Our aim is to conduct a randomized controlled feasibility trial exploring key methodological, design and acceptability issues, in order to subsequently undertake a large-scale randomized controlled trial of the Books Beyond Words booklet for epilepsy.
Genetic Predictors Of Metabolic Side Effects Of Diuretic Therapy, Jorge L. Del Aguila
Genetic Predictors Of Metabolic Side Effects Of Diuretic Therapy, Jorge L. Del Aguila
Dissertations and Theses (Open Access)
Thiazide diuretics are a recommended first-line monotherapy for hypertension (i.e.SBP>140 mmHg or DBP>90 mmHg). Even so, diuretics are associated with adverse metabolic side effects, such as hyperlipidemia, hyperglycemia and hypokalemia which increase the risk of developing type II diabetes. This thesis used three analytical strategies to identify and quantify genetic factors that contribute to the development of adverse metabolic effects due to thiazide diuretic treatment. I performed a genome-wide association study (GWAS) and meta-analysis of the change in fasting plasma glucose and triglycerides in response to HCTZ from two different clinical trials: the Pharmacogenomic Evaluation of Antihypertensive Responses …
A Study Of Joinpoint Models For Longitudinal Data, Libo Zhou
A Study Of Joinpoint Models For Longitudinal Data, Libo Zhou
UNLV Theses, Dissertations, Professional Papers, and Capstones
In many medical studies, data are collected simultaneously on multiple biomarkers from each individual. Levels of these biomarkers are measured periodically over certain time duration, giving rise to longitudinal trajectories. The subjects under study may also be subject to dropout due to several competing causes, the likelihood of which may be affected by the levels of these biomarkers. In this dissertation, we investigate flexible Bayesian modeling of such data, taking into account any available covariate information as well as possible censoring of the drop-out times. We propose joint models for multiple biomarkers with multiple causes of dropout. Our proposed models …
Clinical Trials And Late-Stage Drug Development In Alzheimer’S Disease: An Appraisal From 1984 To 2014, L. S. Schneider, F. Mangialasche, S. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, M. Kivipelto
Clinical Trials And Late-Stage Drug Development In Alzheimer’S Disease: An Appraisal From 1984 To 2014, L. S. Schneider, F. Mangialasche, S. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, M. Kivipelto
Human Clinical Trials Collection
The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease. Since then, despite the evaluation of numerous potential treatments in clinical trials, only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy to allow marketing approval at an international level. Although this is probably because the other drugs tested were ineffective, inadequate clinical development methods have also been blamed for the failures. Here, we review the development of treatments for Alzheimer's disease during the past 30 years, considering the drugs, …
Nudging The Fda, W. Nicholson Price Ii, I. Glenn Cohen
Nudging The Fda, W. Nicholson Price Ii, I. Glenn Cohen
Law Faculty Scholarship
[Excerpt] "The FDA’s regulation of drugs is frequently the subject of policy debate, with arguments falling into two camps. On the one hand, a libertarian view of patients and the health care system holds high the value of consumer choice. Patients should get all the information and the drugs they want; the FDA should do what it can to enforce some basic standards but should otherwise get out of the way. On the other hand, a paternalist view values the FDA’s role as an expert agency standing between patients and a set of potentially dangerous drugs and potentially unscrupulous or …
Lost In Translation: Animal Models And Clinical Trials In Cancer Treatment, Isabella W.Y. Mak, Nathan Evaniew, Michelle Ghert
Lost In Translation: Animal Models And Clinical Trials In Cancer Treatment, Isabella W.Y. Mak, Nathan Evaniew, Michelle Ghert
Human Clinical Trials Collection
Due to practical and ethical concerns associated with human experimentation, animal models have been essential in cancer research. However, the average rate of successful translation from animal models to clinical cancer trials is less than 8%. Animal models are limited in their ability to mimic the extremely complex process of human carcinogenesis, physiology and progression. Therefore the safety and efficacy identified in animal studies is generally not translated to human trials. Animal models can serve as an important source of in vivo information, but alternative translational approaches have emerged that may eventually replace the link between in vitro studies and …